AR068595A1 - Composicion y metodo para el tratamiento o la prevencion de hiperplasia prostatica benigna y sintomas del tracto urinario inferior - Google Patents

Composicion y metodo para el tratamiento o la prevencion de hiperplasia prostatica benigna y sintomas del tracto urinario inferior

Info

Publication number
AR068595A1
AR068595A1 ARP080104272A ARP080104272A AR068595A1 AR 068595 A1 AR068595 A1 AR 068595A1 AR P080104272 A ARP080104272 A AR P080104272A AR P080104272 A ARP080104272 A AR P080104272A AR 068595 A1 AR068595 A1 AR 068595A1
Authority
AR
Argentina
Prior art keywords
composition
urinary tract
benign prostatic
prostatic hyperplasia
lower urinary
Prior art date
Application number
ARP080104272A
Other languages
English (en)
Inventor
Byoung-Ok Ahn
Byoung Gill Kim
Seul-Min Choi
Kyung-Koo Kang
Moo-Hi Yoo
Original Assignee
Dong A Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020080017768A external-priority patent/KR100920125B1/ko
Application filed by Dong A Pharm Co filed Critical Dong A Pharm Co
Publication of AR068595A1 publication Critical patent/AR068595A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente se refiere a una composicion y a un método para tratar o prevenir la hiperplasia prostática benigna (HPB) y los síntomas del tracto urinario inferior (STUI) sin mostrar efectos secundarios, relajando notablemente la musculatura lisa prostática y vesical. Reivindicacion 1: Una composicion para el tratamiento o prevencion de la hiperplasia prostática benigna y los síntomas del tracto urinario inferior, que comprende un compuesto pirazolpirimidinona representado por la formula química (1) y un antagonista del receptor alfa-adrenérgico en una cantidad efectiva. Reivindicacion 3: La composicion de la reivindicacion 1, en la cual el antagonista del receptor alfa-adrenérgico comprende 1-(3-hidroxipropil)-5-{2R-2[2,2,2-trifluoroetoxi)fenoxi]etilamino]propil}-7-indolincarboxamida. Reivindicacion 8: El método de la Reivindicacion 6, en el cual el antagonista del alfa-adrenérgico comprende (R)-5-(2-(2-(2-etoxilfenoxi)etilamino)propil)-2-metoxi bencensulfonamida.
ARP080104272A 2007-10-02 2008-09-30 Composicion y metodo para el tratamiento o la prevencion de hiperplasia prostatica benigna y sintomas del tracto urinario inferior AR068595A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20070099016 2007-10-02
KR1020080017768A KR100920125B1 (ko) 2007-10-02 2008-02-27 양성 전립선 비대증 치료를 위한 피라졸로피리미디논화합물 및 알파 아드레날린성 수용체 길항제를 함유하는약제학적 배합물

Publications (1)

Publication Number Publication Date
AR068595A1 true AR068595A1 (es) 2009-11-18

Family

ID=40526812

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104272A AR068595A1 (es) 2007-10-02 2008-09-30 Composicion y metodo para el tratamiento o la prevencion de hiperplasia prostatica benigna y sintomas del tracto urinario inferior

Country Status (13)

Country Link
US (1) US20100210668A1 (es)
EP (1) EP2192903A4 (es)
JP (1) JP2010540621A (es)
CN (1) CN101815520A (es)
AR (1) AR068595A1 (es)
AU (1) AU2008307905A1 (es)
CA (1) CA2701844A1 (es)
CO (1) CO6270327A2 (es)
IL (1) IL204694A0 (es)
MX (1) MX2010003193A (es)
RU (1) RU2010115647A (es)
TW (1) TW200918072A (es)
WO (1) WO2009045019A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2918245C (en) * 2013-08-01 2022-08-30 Dignify Therapeutics, Inc. Compositions and methods for inducing urinary voiding and defecation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6410554B1 (en) * 1998-03-23 2002-06-25 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
IL132406A0 (en) * 1998-10-21 2001-03-19 Pfizer Prod Inc Treatment of bph with cgmp elevators
KR100353014B1 (ko) * 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
CZ20021151A3 (cs) * 1999-10-11 2003-03-12 Pfizer Inc. 5-(2-substituovaný-5-heterocyklylsulfonylpyrid-3-yl)-dihydropyrazolo[4,3-d]-pyrimidin-7-ony jako inhibitory fosfodiesterasy
RU2006119331A (ru) * 2003-11-03 2007-12-27 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АГОНИСТ β3-АДРЕНОРЕЦЕПТОРА, α-АНТАГОНИСТ И/ИЛИ ИНГИБИТОР 5α-РЕДУКТАЗЫ
JP2005263637A (ja) * 2004-03-16 2005-09-29 Pfizer Inc アトルバスタチンとα１−アドレナリン作動性受容体アンタゴニストとの組み合わせ
WO2005092321A1 (ja) * 2004-03-24 2005-10-06 Kissei Pharmaceutical Co., Ltd. 頻尿または尿失禁の予防または治療用医薬組成物
US20070004745A1 (en) * 2005-03-25 2007-01-04 Schering-Plough Corporation Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors
SG166106A1 (en) * 2005-09-29 2010-11-29 Bayer Schering Pharma Ag Pde inhibitors and combinations thereof for the treatment of urological disorders
WO2007113243A2 (en) * 2006-03-31 2007-10-11 Investigación Y Clínica Andrológicas S.L. Use of pde 5 inhibitors for the treatment of overactive bladder
EP2106792A1 (en) * 2008-04-02 2009-10-07 Pelvipharm Use of a combination of udenafil and alfuzosin or oxybutynin for the treatment of overactive bladder

Also Published As

Publication number Publication date
AU2008307905A1 (en) 2009-04-09
CA2701844A1 (en) 2009-04-09
EP2192903A2 (en) 2010-06-09
CO6270327A2 (es) 2011-04-20
US20100210668A1 (en) 2010-08-19
JP2010540621A (ja) 2010-12-24
RU2010115647A (ru) 2011-11-10
WO2009045019A3 (en) 2009-06-18
CN101815520A (zh) 2010-08-25
MX2010003193A (es) 2010-06-25
WO2009045019A2 (en) 2009-04-09
TW200918072A (en) 2009-05-01
IL204694A0 (en) 2010-11-30
EP2192903A4 (en) 2010-09-29

Similar Documents

Publication Publication Date Title
MA32049B1 (fr) Traitement du cancer avec des combinaisons d'inhibiteurs de topoisomerase et d'inhibiteurs de parp
EA200801897A1 (ru) Ингибиторы mnk2 на основе 8-гетероарилпурина для лечения метаболических нарушений
DOP2009000159A (es) Inhibidores de la poli(adp-ribosa) polimerasa
NO20083235L (no) Anvendelse av kolesterolsenkende midler og H3-reseptorantagonist/invers agonist ved behandling av ikke-alkoholrelatert fettleversykdom
EA201100427A1 (ru) Гетероциклические ингибиторы киназы
TR201900306T4 (tr) Mek inhibitörlerini kullanma yöntemleri.
CO6531498A2 (es) COMBINACIÓN QUE COMPRENDE UN INHIBIDORDE MEK Y UN INHIBIDOR DE B- RAF úTIL EN EL TRATAMIENTO DE TRASTORNOS HIPERPROLIFERATIVOS
MA31335B1 (fr) Procédés de traitement impliquant l'inhibition de pi3k-alpha au moyen d'inhibiteurs de type quinaxoline
AR067495A1 (es) Composiciones farmaceuticas y procedimientode tratamientos de trastornos de ojo seco
DOP2006000074A (es) Combinacion para terapia en hiperplasia benigna de prostata
WO2007024717A3 (en) Agents for preventing and treating disorders involving modulation of the ryr receptors
WO2007112288A3 (en) Cardiovascular composition and use the same for the treatment of alzheimers disease
EA200900571A1 (ru) Композиции chk1 ингибиторов
CR10226A (es) Combinaciones del inhibidor de ang2 y vegf
ECSP088311A (es) Inhibidores de la pde y combinaciones de los mismos para el tratamiento de trastornos urológicos
ECSP109953A (es) Derivados de piridazinona
TNSN07305A1 (fr) Agonistes de pyy et leurs utilisations
MA31663B1 (fr) Dosage oral et interveineux de l'inhibiteur p2y12 reverisble et a action directe
CR20110339A (es) Compuestos útiles para inhibir chk1
NO20064848L (no) Imidazolforbindelser
BRPI0809656B8 (pt) atropisômero, composto, agente profilático ou terapêutico, e, composição farmacêutica
NO20080352L (no) Diclofenacformuleringer og fremgangsmate ved anvendelse
AR071392A1 (es) Derivados de iminopiridina y su uso
EA201001648A1 (ru) Производные пиридазинона
WO2006104870A3 (en) Methods of treating benign prostatic hyperplasia or lower urinary track symptoms by using pde 5 inhibitors

Legal Events

Date Code Title Description
FB Suspension of granting procedure